Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Endometrial Neoplasms 3Obesity 2Endometrial Hyperplasia 2Hyperplasia 1Breast Neoplasms 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × Tirzepatide × Clear all
NCT07257484 2026-03-13

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Weill Medical College of Cornell University

Phase 4 Not yet recruiting
30 enrolled
BreastOther

Breast Neoplasms, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡